NEW YORK, Aug. 20, 2013 /PRNewswire/ -- Today, more than one year after Americord announced the launch of its $80,000 quality guarantee, the company remains the only one in the cord blood banking industry to offer parents this level of financial protection. Its closest competitors, all of which charge parents-to-be significantly higher fees for cord blood banking, offer parents-to-be significantly lower quality guarantees – generally between $25,000 and $50,000.
"Expertise, service, and value are the three pillars that Americord is built upon," said Americord CEO Martin Smithmyer. "We adhere to the highest scientific standards in the industry, we offer the most comprehensive service, and we give parents-to-be the greatest value in the cord blood industry." Americord offers cord blood banking for approximately 50% less than its competitors, and Americord's price includes the cost of a medical courier as well as 20 years of storage in their state-of-the-art CLIA Certified, AABB accredited laboratory.
Leading cord blood banks offer quality guarantees to provide financial protection to parents in the unlikely event that the stem cells they have banked are needed, but, upon medical use, fail to "engraft". "Engrafting" is key to a successful stem cell transplant. Stem cell transplants are a medical therapy that can be used to treat a variety of diseases, including leukemia, lymphoma, and certain genetic diseases such as sickle cell anemia.
Under Americord's quality guarantee, in the event that a client's stem cells fail to engraft, Americord will pay up to $80,000 to defray the cost of the procurement of an alternative source of stem cells or to seek alternative treatment, if medically indicated.
In a blog post Monday, Smithmyer said, "Americord's industry-leading $80,000 quality guarantee is one of many steps we take to offer parents-to-be greater peace of mind and lower financial stress as they prepare for the birth of their child."
Americord is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord's website at cordadvantage.com for more information. You may also find Americord on Facebook and follow the company on Twitter.
Copyright©2012 PR Newswire.
All rights reserved